| Year |
Citation |
Score |
| 2020 |
Pothoulakis I, Nawaz H, Paragomi P, Jeong K, Talukdar R, Kochhar R, Goenka MK, Gulla A, Singh VK, Gonzalez JA, Ferreira M, Barbu ST, Stevens T, Gutierrez SC, Zarnescu NO, ... ... Tang G, et al. Incidence and risk factors of oral feeding intolerance in acute pancreatitis: results from an international, multicenter, prospective cohort study. United European Gastroenterology Journal. 2050640620957243. PMID 32883182 DOI: 10.1177/2050640620957243 |
0.316 |
|
| 2020 |
Swain SM, Tang G, Brauer HA, Goerlitz DS, Lucas PC, Robidoux A, Harris BT, Bandos H, Ren Y, Geyer CE, Rastogi P, Mamounas EP, Wolmark N. NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32371537 DOI: 10.1158/1078-0432.Ccr-20-0152 |
0.324 |
|
| 2020 |
Forsmark CE, Tang G, Xu H, Tuft M, Hughes SJ, Yadav D. The use of pancreatic enzyme replacement therapy in patients with a diagnosis of chronic pancreatitis and pancreatic cancer in the US is infrequent and inconsistent. Alimentary Pharmacology & Therapeutics. PMID 32249970 DOI: 10.1111/Apt.15698 |
0.313 |
|
| 2020 |
Sestak I, Crager M, Cuzick J, Dowsett M, Shak S, Tang G, Gray R, Sparano J. Abstract GS4-03: Validation of the clinical treatment score post 5 years (CTS5) in women with hormone receptor positive, HER2-negative, node-negative disease from the TAILORx study Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Gs4-03 |
0.347 |
|
| 2020 |
Koutroumpakis F, Ahsan M, Yadav D, Rivers CR, Machicado J, Proksell S, Johnston E, Dueker J, Jana H, Phillips AE, Tang G, Babichenko D, Dunn MA, Binion DG. Su1946 IMMUNOGLOBULIN DEFICIENCIES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE; PREVALENCE AND LONG TERM EFFECT ON CLINICAL OUTCOMES Gastroenterology. 158. DOI: 10.1016/S0016-5085(20)32472-0 |
0.304 |
|
| 2020 |
Pothoulakis I, Paragomi P, Tuft M, Archibugi L, Talukdar R, Kochhar R, Goenka MK, Gulla A, Singh V, Gonzalez JA, Bigado MF, Babu S, Stevens T, Nawaz H, Gutierrez SC, ... ... Tang G, et al. Sa1368 ASSOCIATION OF INCREASED SERUM TRIGLYCERIDE LEVELS AND DISEASE SEVERITY IN ACUTE PANCREATITIS: RESULTS FROM AN INTERNATIONAL, MULTICENTER COHORT STUDY Gastroenterology. 158. DOI: 10.1016/S0016-5085(20)31534-1 |
0.308 |
|
| 2019 |
Matta B, Gougol A, Gao X, Reddy N, Talukdar R, Kochhar R, Goenka MK, Gulla A, Gonzalez JA, Singh VK, Ferreira M, Stevens T, Barbu ST, Nawaz H, Gutierrez SC, ... ... Tang G, et al. Worldwide Variations in Demographics, Management, and Outcomes of Acute Pancreatitis. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association. PMID 31712075 DOI: 10.1016/J.Cgh.2019.11.017 |
0.305 |
|
| 2019 |
Swain SM, Tang G, Lucas PC, Robidoux A, Goerlitz D, Harris BT, Bandos H, Geyer CE, Rastogi P, Mamounas EP, Wolmark N. Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination. Breast Cancer Research and Treatment. PMID 31428908 DOI: 10.1007/S10549-019-05398-3 |
0.343 |
|
| 2019 |
Schwarzenberg SJ, Uc A, Zimmerman B, Wilschanski M, Wilcox CM, Whitcomb DC, Werlin SL, Troendle D, Tang G, Slivka A, Singh VK, Sherman S, Shah U, Sandhu BS, Romagnuolo J, et al. Chronic Pancreatitis: Pediatric and Adult Cohorts Show Similarities in Disease Progress Despite Different Risk Factors. Journal of Pediatric Gastroenterology and Nutrition. 68: 566-573. PMID 30897605 DOI: 10.1097/Mpg.0000000000002279 |
0.317 |
|
| 2018 |
Greer JB, Greer P, Sandhu BS, Alkaade S, Wilcox CM, Anderson MA, Sherman S, Gardner TB, Lewis MD, Guda NM, Muniraj T, Conwell D, Cote GA, Forsmark CE, Banks PA, ... Tang G, et al. Nutrition and Inflammatory Biomarkers in Chronic Pancreatitis Patients. Nutrition in Clinical Practice : Official Publication of the American Society For Parenteral and Enteral Nutrition. PMID 30101991 DOI: 10.1002/Ncp.10186 |
0.302 |
|
| 2018 |
Swain SM, Tang G, Lucas PC, Robidoux A, Goerlitz D, Harris BT, Bandos H, Geyer CE, Rastogi P, Mamounas EP, Wolmark N. Intrinsic subtypes of HER2-positive breast cancer and their associations with pathologic complete response (pCR) and outcomes: Findings from NSABP B-41, a randomized neoadjuvant trial. Journal of Clinical Oncology. 36: 580-580. DOI: 10.1200/Jco.2018.36.15_Suppl.580 |
0.351 |
|
| 2017 |
Mamounas EP, Tang G, Paik S, Baehner FL, Liu Q, Jeong JH, Kim SR, Butler SM, Jamshidian F, Cherbavaz DB, Sing AP, Shak S, Julian TB, Lembersky BC, Lawrence Wickerham D, et al. 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology. Breast Cancer Research and Treatment. PMID 29128898 DOI: 10.1007/S10549-017-4550-8 |
0.346 |
|
| 2017 |
Bellin MD, Whitcomb DC, Abberbock J, Sherman S, Sandhu BS, Gardner TB, Anderson MA, Lewis MD, Alkaade S, Singh VK, Baillie J, Banks PA, Conwell D, Cote GA, Guda NM, ... ... Tang G, et al. Patient and Disease Characteristics Associated With the Presence of Diabetes Mellitus in Adults With Chronic Pancreatitis in the United States. The American Journal of Gastroenterology. PMID 28741615 DOI: 10.1038/Ajg.2017.181 |
0.315 |
|
| 2017 |
Mamounas EP, Liu Q, Paik S, Baehner FL, Tang G, Jeong JH, Kim SR, Butler SM, Jamshidian F, Cherbavaz DB, Sing AP, Shak S, Julian TB, Lembersky BC, Wickerham DL, et al. 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy. Journal of the National Cancer Institute. 109. PMID 28122895 DOI: 10.1093/Jnci/Djw259 |
0.332 |
|
| 2017 |
Machicado JD, Gougol A, Dugum M, Manzo CE, Tang G, Whitcomb DC, Yadav D, Slivka A, Papachristou GI. Different Demographic, Clinical and Severity Profile between Patients with Recurrent and First Attack of Acute Pancreatitis (AP) Gastroenterology. 152. DOI: 10.1016/S0016-5085(17)31239-8 |
0.317 |
|
| 2016 |
Bear HD, Tang G, Rastogi P, Geyer CE, Zoon CK, Kidwell KM, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, et al. The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40. Annals of Surgical Oncology. PMID 27864694 DOI: 10.1245/S10434-016-5662-9 |
0.316 |
|
| 2016 |
Wilcox CM, Sandhu BS, Singh V, Gelrud A, Abberbock JN, Sherman S, Cote GA, Al-Kaade S, Anderson MA, Gardner TB, Lewis MD, Forsmark CE, Guda NM, Romagnuolo J, Baillie J, ... ... Tang G, et al. Racial Differences in the Clinical Profile, Causes, and Outcome of Chronic Pancreatitis. The American Journal of Gastroenterology. PMID 27527745 DOI: 10.1038/Ajg.2016.316 |
0.322 |
|
| 2016 |
Liu Q, Tang G, Costantino JP, Chang CCH. Robust prediction of the cumulative incidence function under non-proportional subdistribution hazards Canadian Journal of Statistics. 44: 127-141. DOI: 10.1002/Cjs.11280 |
0.317 |
|
| 2015 |
Cecchini R, Swain SM, Costantino JP, Rastogi P, Jeong JH, Anderson SJ, Tang G, Geyer CE, Lembersky BC, Romond EH, Paterson AH, Wolmark N. Body mass index at diagnosis and breast cancer survival prognosis in clinical trial populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 26545405 DOI: 10.1158/1055-9965.Epi-15-0334-T |
0.336 |
|
| 2015 |
Bear HD, Tang G, Rastogi P, Geyer CE, Liu Q, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. The Lancet. Oncology. 16: 1037-48. PMID 26272770 DOI: 10.1016/S1470-2045(15)00041-8 |
0.35 |
|
| 2015 |
Bear HD, Tang G, Rastogi P, Geyer CE, Liu Q, Robidoux A, Atkins JN, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, et al. Abstract PD2-1: The effect on overall and disease-free survival (OS & DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40 Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-Pd2-1 |
0.311 |
|
| 2015 |
Mamounas E, Wolmark N, Baehner F, Butler S, Tang G, Jamshidian F, Sing A, Shak S, Paik S. P264 Predicting late distant recurrence risk in ER+ breast cancer after five years of tamoxifen The Breast. 24: S117. DOI: 10.1016/S0960-9776(15)70296-1 |
0.312 |
|
| 2014 |
Crager MR, Tang G. Patient-specific meta-analysis for risk assessment using multivariate proportional hazards regression. Journal of Applied Statistics. 41: 2676-2695. PMID 26664111 DOI: 10.1080/02664763.2014.925102 |
0.317 |
|
| 2014 |
Swain SM, Tang G, Geyer CE. Reply to E.J. Moylan et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 606-7. PMID 24419136 DOI: 10.1200/Jco.2013.53.8744 |
0.349 |
|
| 2014 |
Wolmark N, Mamounas EP, Baehner FL, Butler SM, Tang G, Jamshidian F, Sing AP, Shak S, Paik S. Recurrence score and quantitative ER expression to predict in late distant recurrence risk in ER+ BC after 5 years of tamoxifen. Journal of Clinical Oncology. 32: 11024-11024. DOI: 10.1200/Jco.2014.32.15_Suppl.11024 |
0.322 |
|
| 2013 |
Robidoux A, Tang G, Rastogi P, Geyer CE, Azar CA, Atkins JN, Fehrenbacher L, Bear HD, Baez-Diaz L, Sarwar S, Margolese RG, Farrar WB, Brufsky AM, Shibata HR, Bandos H, et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. The Lancet. Oncology. 14: 1183-92. PMID 24095300 DOI: 10.1016/S1470-2045(13)70411-X |
0.332 |
|
| 2013 |
Swain SM, Tang G, Geyer CE, Rastogi P, Atkins JN, Donnellan PP, Fehrenbacher L, Azar CA, Robidoux A, Polikoff JA, Brufsky AM, Biggs DD, Levine EA, Zapas JL, Provencher L, et al. Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 3197-204. PMID 23940225 DOI: 10.1200/Jco.2012.48.1275 |
0.331 |
|
| 2013 |
Cecchini R, Swain S, Costantino J, Rastogi P, Jeong J, Anderson S, Tang G, Geyer C, Lembersky B, Romond E, Paterson A, Wolmark N. Abstract PD2-1: Body mass index at diagnosis and breast cancer survival prognosis among clinical trial populations: Results from NSABP B-30, B-31, B-34, and B-38 Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-Pd2-1 |
0.348 |
|
| 2012 |
Tang G, Paik S, Baehner FL, Liu Q, Jeong JH, Kim SR, Butler SM, Jamshidian F, Cherbavaz DB, Shak S, Julian TB, Lembersky BC, Wickerham DL, Costantino JP, Wolmark N. Prognostic impact of the 21-gene recurrence score (RS) on disease-free and overall survival of node-positive, ER-positive breast cancer patients (pts) treated with adjuvant chemotherapy: Results from NSABP B-28. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 1. PMID 28146698 DOI: 10.1200/Jco.2012.30.27_Suppl.1 |
0.323 |
|
| 2012 |
Tang G, Geyer CE, Rastogi P, Atkins JN, Donnellan PP, Fehrenbacher L, Azar CA, Robidoux A, Polikoff J, Brufsky A, Biggs DD, Levine EA, Zapas JL, Provencher L, Perez EA, et al. NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC→paclitaxel (P) plus gemcitabine (G) with DD AC→P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: LBA1000. PMID 28140798 DOI: 10.1200/Jco.2012.30.15_Suppl.Lba1000 |
0.329 |
|
| 2012 |
Bear HD, Tang G, Rastogi P, Geyer CE, Robidoux A, Atkins JN, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. The New England Journal of Medicine. 366: 310-20. PMID 22276821 DOI: 10.1056/NEJMoa1111097 |
0.316 |
|
| 2012 |
Mamounas EP, Tang G, Paik S, Baehner FL, Liu Q, Jeong J, Kim S, Butler SM, Jamshidian F, Cherbavaz DB, Sing AP, Shak S, Julian TB, Lembersky BC, Wickerham DL, et al. Abstract P6-07-01: Prognostic impact of the 21-gene Recurrence Score (RS) on loco-regional recurrence (LRR) of node-positive, ER-positive breast cancer patients (pts) treated with adjuvant chemotherapy: Results from NSABP B-28 Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P6-07-01 |
0.33 |
|
| 2011 |
Tang G, Cuzick J, Costantino JP, Dowsett M, Forbes JF, Crager M, Mamounas EP, Shak S, Wolmark N. Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4365-72. PMID 22010013 DOI: 10.1200/Jco.2011.35.3714 |
0.368 |
|
| 2011 |
Tang G, Shak S, Paik S, Anderson SJ, Costantino JP, Geyer CE, Mamounas EP, Wickerham DL, Wolmark N. Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. Breast Cancer Research and Treatment. 127: 133-42. PMID 21221771 DOI: 10.1007/S10549-010-1331-Z |
0.345 |
|
| 2011 |
Shen K, Tang G, Kim C, Pogue-Geile K, Anderson S, Constantino J, Bear H, Song N, Tian C, Gabrin M, Zhang Y, Geyer C, Wolmark N. P1-06-15: A Genomic Predictor Developed from Breast Cancer Cell Lines Predicts Both Disease-Free Survival and Overall Survival in Breast Cancer Patients Treated with Doxorubicin and Cyclophosphamide: A Collaborative Project of the NSABP and Precision Therapeutics. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P1-06-15 |
0.353 |
|
| 2011 |
Schnatter R, Rushton L, Glass D, Tang G. Lymphohaematopoietic cancers and benzene: a pooled analysis of petroleum workers Occupational and Environmental Medicine. 68. DOI: 10.1136/Oemed-2011-100382.113 |
0.333 |
|
| 2010 |
Mamounas EP, Tang G, Fisher B, Paik S, Shak S, Costantino JP, Watson D, Geyer CE, Wickerham DL, Wolmark N. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 1677-83. PMID 20065188 DOI: 10.1200/Jco.2009.23.7610 |
0.362 |
|
| 2010 |
Tang G, Costantino J, Crager M, Shak S, Wolmark N. Abstract S4-9: Comparing the Prediction of Chemotherapy Benefit in Patients with Node-Negative, ER-Positive Breast Cancer Using the Recurrence Score and a New Measure That Integrates Clinical and Pathologic Factors with the Recurrence Score Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-S4-9 |
0.371 |
|
| 2008 |
Ross DT, Kim CY, Tang G, Bohn OL, Beck RA, Ring BZ, Seitz RS, Paik S, Costantino JP, Wolmark N. Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 6602-9. PMID 18927301 DOI: 10.1158/1078-0432.Ccr-08-0647 |
0.36 |
|
| 2008 |
Paik S, Tang G, Fumagalli D. An ideal prognostic test for estrogen receptor-positive breast cancer? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4058-9. PMID 18678837 DOI: 10.1200/Jco.2008.16.7528 |
0.33 |
|
| 2007 |
Ross DT, Kim C, Tang G, Mejia OM, Beck RA, Ring BZ, Seitz RS, Paik S, Constantino JP, Wolmark N. Chemosensitivity and stratification by a five monoclonal antibody IHC test in the NSABP B20 trial Journal of Clinical Oncology. 25: 529-529. DOI: 10.1200/Jco.2007.25.18_Suppl.529 |
0.314 |
|
| 2006 |
Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE, Wickerham DL, Wolmark N. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 3726-34. PMID 16720680 DOI: 10.1200/Jco.2005.04.7985 |
0.346 |
|
| 2004 |
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. The New England Journal of Medicine. 351: 2817-26. PMID 15591335 DOI: 10.1056/Nejmoa041588 |
0.358 |
|
| 2004 |
Land SR, Kopec JA, Yothers G, Anderson S, Day R, Tang G, Ganz PA, Fisher B, Wolmark N. Health-related quality of life in axillary node-negative, estrogen receptor-negative breast cancer patients undergoing AC versus CMF chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project B-23. Breast Cancer Research and Treatment. 86: 153-64. PMID 15319567 DOI: 10.1023/B:Brea.0000032983.87966.4E |
0.351 |
|
| Show low-probability matches. |